News
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
Heidelberg Pharma presents new clinical data on lead ADC candidate HDP-101 at IMS 2024, showing complete remission in one patient. Company developing innovative ADCs for cancer treatment -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
Heidelberg Pharma AG adjusts its 2024 guidance, expecting sales and other income between EUR 10.0 - 12.0 million and operating expenses between EUR 30.0 - 33.0 million. The company anticipates secured financing until mid-2025 -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
Heidelberg Pharma announces new clinical data on lead ATAC candidate HDP-101 to be presented at International Myeloma Society Annual Meeting 2024 -
-
